STRO vs TYL · rev $62.0M vs P/E 89, rev $2.14B
Sutro Biopharma (STRO) versus Tyler Technologies Inc (TYL) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Tyler Technologies Inc (TYL) is a software - application company listed on US.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported TYL revenue for 2024-12-31 was $2.14B. Net income was $263.0M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
STRO currently screens at market cap $470.8M. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
Not investment advice. Open the STRO and TYL stock pages for the full models.
Not investment advice.